Compare PTCT & HCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTCT | HCC |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Coal Mining |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.7B |
| IPO Year | 2006 | 2017 |
| Metric | PTCT | HCC |
|---|---|---|
| Price | $78.64 | $90.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 7 |
| Target Price | $80.65 | ★ $95.29 |
| AVG Volume (30 Days) | ★ 1.5M | 807.6K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.36% |
| EPS Growth | ★ 264.48 | N/A |
| EPS | N/A | ★ 1.37 |
| Revenue | $264,734,000.00 | ★ $1,310,043,000.00 |
| Revenue This Year | N/A | $59.95 |
| Revenue Next Year | $17.70 | $8.77 |
| P/E Ratio | ★ N/A | $69.57 |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $43.18 | $43.14 |
| 52 Week High | $87.50 | $110.39 |
| Indicator | PTCT | HCC |
|---|---|---|
| Relative Strength Index (RSI) | 63.26 | 45.42 |
| Support Level | $73.41 | $80.15 |
| Resistance Level | $79.67 | $103.04 |
| Average True Range (ATR) | 3.08 | 4.93 |
| MACD | 0.67 | -1.18 |
| Stochastic Oscillator | 89.41 | 2.27 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Warrior Met Coal Inc produces and exports met or steelmaking coal, which is used as a component for steel production by metal manufacturers in Europe, South America, and Asia. The company is involved in longwall mining operations in its underground mines based in Alabama, Mine No. 4, Mine No. 7, and Blue Creek. Additionally, its natural gas operations remove and sell natural gas from owned and leased coal seams by reducing natural gas levels in its mines. The company generates revenue mainly through the production of steelmaking coal for sale to the steel industry. Geographically, the firm generates maximum revenue from its customers in Asia, followed by Europe, South America, and the United States.